Spherical Nucleic Acid Constructs for Localized TLR Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccines and TLR agonists fail to induce effective immune responses against intracellular pathogens and cancers due to toxicity concerns and inefficiencies, particularly with TLR 7/8 and 9 agonists, necessitating the development of safer and more potent immunostimulatory compounds.
Innovation Solution
Nanoscale constructs with a corona of nucleic acid-interacting complexes, including TLR agonists, are developed with a surface density of at least 0.3 pmol/cm², incorporating antigens and optionally a metallic core, to enhance immune activation and antigen presentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR 7/8 and 9 agonists are used to induce immune responses, then immune activation is enhanced, but toxicity and off-target effects increase
Solution Approach 1:
The patent applies local quality by creating heterogeneous nanoscale constructs with specific surface compositions. The constructs have a core surrounded by a corona containing TLR agonists at controlled surface densities (at least 0.3 pmol/cm²), while incorporating antigens and optional metallic cores. This spatial organization ensures that immunostimulatory activity is concentrated at the surface interface where it can effectively activate immune cells, while the internal structure provides stability and controlled release, thereby enhancing efficacy while reducing systemic toxicity.
Solution Approach 2:
The patent employs parameter changes by precisely controlling the surface density of TLR agonists on the nanoscale construct surface (at least 0.3 pmol/cm²). This parameter optimization allows sufficient immune activation while avoiding excessive dosing that would cause toxicity. The nanoscale size parameter (typically 10-100 nm) is also critical, as it enables cellular uptake and targeted delivery to immune cells, improving efficacy while reducing off-target effects compared to larger particulate systems.
2Reliability
If conventional vaccine formulations are used, then manufacturing is simpler, but immune response efficacy is insufficient
Solution Approach 1:
The patent applies the nested doll principle by creating hierarchical nanoscale constructs with multiple functional components organized in concentric layers. The structure typically includes an inner core (which may be metallic or polymeric) surrounded by a corona layer containing TLR agonists and antigens. This nested architecture allows simultaneous incorporation of multiple functional elements (adjuvant, antigen, targeting moieties) in a compact format that enhances immune activation while maintaining manufacturability through established nanoparticle synthesis methods.
Solution Approach 2:
The patent employs composite materials by combining different materials with complementary properties in the nanoscale construct. This may include metallic cores (gold, silver, iron oxide) providing stability and magnetic properties, polymeric matrices for controlled release, and surface-functionalized TLR agonists and antigens. The composite structure synergistically combines the advantages of each material: structural integrity from the core, controlled release from the polymer matrix, and immunostimulatory activity from the surface-functionalized molecules, thereby achieving superior efficacy compared to conventional single-material vaccine formulations.
Data Source
AI summary
Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof. The compositions of the invention are useful for activating agonists of nucleic acid interacting complexes, such as TLRs, stimulating an immune response, and treating diseases such as infectious disease, cancer, allergies, allergic diseases, and autoimmune disease